Updated on 2024/04/05


HAYAI Shunsaku
Nagoya University Hospital Respiratory Medicine Assistant professor of hospital
Assistant professor of hospital

Degree 1

  1. 学士 ( 2011.3   名古屋大学 ) 

Research Interests 1

  1. 肺癌

Research Areas 1

  1. Life Science / Respiratory medicine  / lung cancer

Education 1

  1. Nagoya University

    2005.4 - 2011.3

Professional Memberships 3

  1. 日本呼吸器学会   専門医

  2. 日本臨床腫瘍学会   がん薬物療法専門医 指導医

  3. 日本内科学会   総合内科専門医


Papers 6

  1. Pneumocystis pneumonia in a patient with severe generalized pustular psoriasis treated with biologics

    Noguchi, H; Takeichi, T; Hayai, S; Yoshikawa, M; Muro, Y; Akiyama, M

    JOURNAL OF DERMATOLOGY   Vol. 51 ( 4 ) page: e112 - e114   2023.10

     More details

  2. Metabolic barriers in non-small cell lung cancer with <i>LKB1</i> and/or <i>KEAP1</i> mutations for immunotherapeutic strategies

    Tanaka, I; Koyama, J; Itoigawa, H; Hayai, S; Morise, M

    FRONTIERS IN ONCOLOGY   Vol. 13   page: 1249237   2023.8

     More details

  3. Amelanotic Malignant Melanoma with a <i>BRAF V600E</i> Mutation Mimicking Primary Lung Cancer

    Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Kim Deoksu, Shimoyama Yoshie, Hashimoto Naozumi

    Internal Medicine   Vol. 61 ( 5 ) page: 703 - 708   2022.3

     More details

    Language:English   Publisher:The Japanese Society of Internal Medicine  

    <p>Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a <i>BRAF V600E</i> mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with <i>BRAF V600E</i> mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression. </p>

    DOI: 10.2169/internalmedicine.6657-20

    Web of Science



    CiNii Research

  4. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data

    Ito Kentaro, Murotani Kenta, Kubo Akihito, Kunii Eiji, Taniguchi Hirokazu, Shindoh Joe, Asada Kazuhiro, Imaizumi Kazuyoshi, Takahashi Kosuke, Karayama Masato, Okuno Motoyasu, Inui Naoki, Hataji Osamu, Morikawa Sayako, Hayai Shunsaku, Suda Takafumi, Abe Takashi, Tsuda Takeshi, Yamagichi Teppei, Kimura Tomoki, Oya Yuko, Yoshida Tatsuya, Hida Toyoaki

    CANCER SCIENCE   Vol. 111 ( 10 ) page: 3705 - 3713   2020.10

     More details

    Language:English   Publisher:Cancer Science  

    We constructed a data set of EGFR-mutant non–small-cell lung carcinoma (NSCLC) patients, and compared the overall survival of first-generation (1G), and second-generation (2G) EGFR-tyrosine kinase inhibitors (TKIs) in clinical practice using a propensity score. We reviewed the clinical data of consecutive EGFR-mutated NSCLC patients who received EGFR-TKI therapy between January 2008 and August 2017 at 11 institutions in Japan. The primary endpoint was overall survival (OS). When comparing OS between 1G and 2G EGFR-TKIs, propensity score analyses were performed using 2 methods: matching and inverse probability of treatment weighting (IPTW). (Clinical Trial information: UMIN000030121) In total, 1400 patients from 11 institutions were enrolled in this study, and the data from the 1366 patients who received only EGFR-TKI therapy were analyzed (gefitinib [GEF], N = 732; erlotinib [ERL], N = 416; afatinib, N = 218). Median OS times (months [95%CI]) were 29.7 [27.5-33.5] in the 1G group (gefitinib, 32.0 [28.1-35.8]; erlotinib, 27.5 [23.9-31.7]), and 38.6 [32.2-NR] in the 2G group (afatinib), respectively. The trend of longer OS for afatinib against 1G EGFR-TKIs remained, even after adjusted by propensity score. (unadjusted, hazard ratio [HR] 0.676, P =.0023; adjusted by IPTW, HR 0.685 P <.0001; adjusted by matching, HR 0.725, P =.0418). Exploratory analysis showed that OS using the 2G EGFR-TKI was superior to that of the 1G EGFR-TKIs, suggesting the potential of sequential therapy of 2G EGFR-TKI followed by osimertinib. (HR 0.419, P =.0519) Real-world data analysis using 1354 data records, using propensity scoring, indicated that 2G EGFR-TKI had a trend of longer OS compared with 1G EGFR-TKIs.

    DOI: 10.1111/cas.14560

    Web of Science



  5. An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

    Miyazaki Shinichi, Kuno Yasumasa, Hayai Shunsaku, Teramachi Ryo, Yamashita Ryo, Saito Yusuke, Higuchi Kosuke, Nara Yoshiharu, Ikeda Takuya

    JOURNAL OF MEDICAL CASE REPORTS   Vol. 14 ( 1 ) page: 122   2020.8

     More details

    Language:English   Publisher:Journal of Medical Case Reports  

    Background: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. Almost all patients who initially respond to an epidermal growth factor receptor tyrosine kinase inhibitor subsequently report disease progression. Epidermal growth factor receptor-dependent resistance mechanisms, bypass pathway activation, and histological transformation have been reported with osimertinib therapy. Case presentation: We report a case of a 64-year-old Asian man with epidermal growth factor receptor T790M-positive adenocarcinoma that transformed to epidermal growth factor receptor T790M-negative large-cell neuroendocrine carcinoma after osimertinib therapy. A prompt rebiopsy revealed a rare mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitor, and subsequently treatment with carboplatin and etoposide was effective. Conclusions: Despite the promising emergence of circulating tumoral DNA testing, this case report emphasizes the importance of rebiopsy of a progressive epidermal growth factor receptor-mutant tumor.

    DOI: 10.1186/s13256-020-02447-0

    Web of Science



  6. High-flow nasal cannula oxygen therapy in acute respiratory failure

    Yokoyama T., Hayai S.

    Respiration and Circulation   Vol. 64 ( 12 ) page: 1167 - 1172   2016.12

     More details

    Publisher:Respiration and Circulation  


▼display all

Presentations 7

  1. Combination therapy with cisplatin and inhibition stress granule formation in lung cancer cells

    Hayai, S; Suzuki, M; Shinjo, K; Kondo, Y

    CANCER SCIENCE  2023.2 

     More details

    Event date: 2023.2


  2. Complications of lung cancer in the clinical course of interstitial lung disease

    Noguchi, Y; Takei, R; Hayai, S; Oi, H; Yamano, Y; Yokoyama, T; Matsuda, T; Kataoka, K; Kimura, T; Kondoh, Y


     More details

    Event date: 2022.9

    DOI: 10.1183/13993003.congress-2022.210

  3. Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation

    Tanaka, K; Inui, N; Asada, K; Abe, T; Hataji, O; Hayai, S; Ito, K; Imaizumi, K; Kimura, T; Kubo, A; Kunii, E; Murotani, K; Okuno, M; Oya, Y; Shindoh, J; Taniguchi, H; Tsuda, T; Yamaguchi, T; Hida, T; Suda, T

    ANNALS OF ONCOLOGY  2018.11 

     More details

    Event date: 2018.11

  4. Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC

    Ito, K; Murotani, K; Kubo, A; Kunii, E; Taniguchi, H; Shindo, J; Asada, K; Imaizumi, K; Tanaka, K; Inui, N; Okuno, M; Hataji, O; Hayai, S; Abe, T; Kimura, T; Tsuda, T; Yamaguchi, T; Oya, Y; Yoshida, T; Hida, T

    ANNALS OF ONCOLOGY  2018.10 

     More details

    Event date: 2018.10

  5. Lung Cancer in Patients with Interstitial Lung Disease: Clinical Characteristics and Impact on Survival International conference

    Hayai, S; Taniguchi, H; Kondoh, Y; Kimura, T; Kataoka, K; Matsuda, T; Yokoyama, T


     More details

    Event date: 2017.11

    Presentation type:Oral presentation (general)  

    DOI: 10.1016/j.jtho.2017.09.1731

  6. Prognostic Factors including EGFR Status in Advanced Lung Adenocarcinoma Patients International conference

    Hayai, S; Taniguchi, H; Kondoh, Y; Kimura, T; Kataoka, K; Matsuda, T; Yokoyama, T


     More details

    Event date: 2015.9

    Presentation type:Oral presentation (general)  


    Hayai, S; Taniguchi, H; Kondoh, Y; Kimura, T; Kataoka, K; Matsuda, T; Yokoyama, T

    RESPIROLOGY  2013.11 

     More details

    Event date: 2013.11

    Presentation type:Oral presentation (general)  

▼display all